OPKO Health, Inc. Total Liabilities and Equity
OPKO Health, Inc. (OPK) had Total Liabilities and Equity of $1.83 billion as of 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-28
- 2026-06-30: Liabilities and Equity $1.83B.
- 2026-03-31: Liabilities and Equity $1.86B.
- 2025-12-31: Liabilities and Equity $1.93B.
- 2025-09-30: Liabilities and Equity $2.00B.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $1.83B 10-Q/A · filed 2026-08-28 | |
| 2026-03-31 | $1.86B 10-Q/A · filed 2026-08-28 | |
| 2025-12-31 | $1.93B 10-Q/A · filed 2026-08-28 | |
| 2025-09-30 | $2.00B 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $1.97B 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $2.13B 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $2.20B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $2.26B 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $1.98B 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $1.97B 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $2.01B 10-K · filed 2025-03-03 | |
| 2023-09-30 | $2.06B 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $2.16B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $2.17B 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $2.17B 10-K · filed 2024-03-01 | |
| 2022-09-30 | $2.22B 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $2.37B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $2.31B 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $2.40B 10-K · filed 2023-02-27 | |
| 2021-09-30 | $2.42B 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $2.42B 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $2.52B 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $2.47B 10-K · filed 2022-03-01 | |
| 2020-09-30 | $2.37B 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $2.32B 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $2.23B 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $2.31B 10-K · filed 2021-02-18 | |
| 2019-09-30 | $2.37B 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $2.46B 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $2.58B 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $2.45B 10-K · filed 2020-03-02 | |
| 2018-09-30 | $2.48B 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $2.53B 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $2.58B 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $2.59B 10-K · filed 2019-03-01 | $2.58B 10-K · filed 2018-03-01 |
| 2017-09-30 | $2.72B 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $2.77B 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $2.76B 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $2.77B 8-K · filed 2019-01-29 | |
| 2016-09-30 | $2.80B 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $2.77B 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $2.79B 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $2.80B 10-K · filed 2017-03-01 | $2.80B 10-K · filed 2016-02-29 |
| 2015-09-30 | $3.02B 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $1.53B 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $1.51B 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $1.27B 10-K · filed 2016-02-29 | |
| 2014-09-30 | $1.30B 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $1.33B 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $1.36B 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $1.39B 10-K · filed 2015-02-27 | |
| 2013-09-30 | $1.38B 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $641.08M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $653.93M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $289.83M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $250.02M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $230.47M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $231.57M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $229.49M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $151.00M 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $160.42M 10-Q · filed 2011-08-08 | |
| 2010-12-31 | $77.85M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |